LOS ANGELES, July 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Fortrea Holdings, Inc. ("Fortrea" or "the Company") (NASDAQ: FTRE) for violations of the federal securities laws.Shareholders who purchased the Company's securities between July 3, 2023 and February 28, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 1, 2025. DJS Law Group CASE DETAILS:  The complaint alleges that the Company made false and misleading s ...

LOS ANGELES, July 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the federal securities laws.Shareholders who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.CASE DETAILS:  The complaint alleges that the Company made false and misleading statements to the ma ...

Core Viewpoint - Hims & Hers Health, Inc. is facing securities class action lawsuits due to allegations of failing to disclose material information during the class period, which has resulted in significant financial losses for investors [3][4]. Group 1: Legal Actions - Investors have until August 25, 2025, to file lead plaintiff applications in the ongoing securities class action lawsuits against Hims & Hers Health, Inc. for purchases made between April 29, 2025, and June 23, 2025 [1][2]. - The lawsuits are pending in the United States District Court for the Northern District of California, with the first case filed being Sookdeo v. Hims & Hers Health, Inc. [5]. Group 2: Company Issues - Novo Nordisk terminated its partnership with Hims on June 23, 2025, citing violations of laws regarding the sale of compounded drugs and concerns over patient safety due to deceptive marketing practices [4]. - Following the announcement of the partnership termination, Hims' share price dropped by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025, amid unusually high trading volume [4]. Group 3: Law Firm Background - Kahn Swick & Foti, LLC, the law firm handling the lawsuits, is recognized as one of the top boutique securities litigation firms in the U.S., serving both institutional and retail investors [5].

Core Viewpoint - Compass Diversified Holdings is facing securities class action lawsuits due to alleged failure to disclose material information during the class period from March 1, 2023, to May 7, 2025, which has resulted in significant financial losses for investors [1][3]. Group 1: Legal Actions - Investors have until July 8, 2025, to file lead plaintiff applications in the ongoing class action lawsuits against Compass Diversified Holdings [1][2]. - The lawsuits are based on claims that Compass and its executives violated federal securities laws by not disclosing critical information during the specified class period [3]. Group 2: Company Disclosure and Impact - On May 7, 2025, Compass disclosed that its financial statements for fiscal 2024 would require restatement due to an ongoing internal investigation into its subsidiary, Lugano Holding, Inc. [4]. - The investigation revealed irregularities in Lugano's financing, accounting, and inventory practices, leading to the resignation of Lugano's founder and CEO, Moti Ferder [4]. - Following this announcement, Compass' share price dropped approximately 62%, from $17.25 to $6.55 per share within a day [4]. Group 3: Firm Background - Kahn Swick & Foti, LLC is a prominent securities litigation law firm involved in representing investors in cases of corporate fraud and malfeasance [5]. - The firm has been recognized among the top 10 firms nationally based on total settlement value [5].

Core Viewpoint - A class action lawsuit has been filed against Petco Health and Wellness Company, Inc. for allegedly making materially false and misleading statements regarding its business operations and prospects during the pandemic [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of California on behalf of all individuals and entities who purchased Petco securities between January 14, 2021, and June 5, 2025 [1]. - Investors have until August 29, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against Petco - The lawsuit claims that Petco's pandemic-related growth was unsustainable and that its business model focused on premium pet food was flawed [3]. - It is alleged that the strength of Petco's differentiated product strategy was overstated [3]. - The defendants are accused of downplaying the severity of operational issues and the necessary changes to address them, which could negatively impact Petco's comparable sales [3]. - The lawsuit asserts that Petco's ability to achieve sustainable and profitable growth was overstated [3]. Contact Information - For those affected or seeking more information, contact details for Bragar Eagel & Squire, P.C. are provided, including email and phone number [4][7].

Core Viewpoint - The article discusses the investigation by Monteverde & Associates PC into the proposed sale of Sage Therapeutics, Inc. to Supernus Pharmaceuticals, Inc., focusing on the financial implications for current shareholders and the contingent value rights associated with the transaction [1]. Company Overview - Sage Therapeutics, Inc. is involved in a proposed sale to Supernus Pharmaceuticals, Inc. Current shareholders are set to receive $8.50 per share in cash, along with a non-tradable contingent value right worth up to $3.50 per share [1]. Financial Details - The contingent value right includes three potential cash payments: - $0.50 upon the first commercial sale of the drug Zurzuvae in Japan by June 30, 2026 - $1.00 when net sales of Zurzuvae reach or exceed $300 million in the U.S. by December 31, 2028 - $1.00 when net sales of Zurzuvae reach or exceed $375 million in the U.S. by December 31, 2030 [1]. Legal Context - Monteverde & Associates PC is recognized as a top firm in securities class action services and has a successful track record in recovering money for shareholders [1].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in its stock price following the termination of its partnership with Novo Nordisk [2][3]. Group 1: Company Actions and Events - On April 29, 2025, Hims announced a collaboration with Novo Nordisk to sell a bundled offering of Wegovy on its platform [2]. - On June 23, 2025, Novo Nordisk terminated its partnership with Hims, citing deceptive promotion and safety risks associated with Hims' products [2]. - Following the termination announcement, Hims' share price fell by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025 [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that Hims made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specific allegations include Hims' engagement in deceptive practices regarding the sale of knockoff Wegovy versions and the risk of partnership termination with Novo Nordisk [3]. - The lawsuit claims that Hims' positive statements about its business lacked a reasonable basis due to these undisclosed risks [3].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during the specified Class Period from June 22, 2023, to June 24, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false and misleading statements about ELEVIDYS, which is intended for patients with Duchenne muscular dystrophy, including significant safety risks and failure to detect severe side effects [5]. - It is alleged that the adverse events from ELEVIDYS treatment would lead to a halt in recruitment and dosing in trials, attract regulatory scrutiny, and increase risks around the therapy's approvals [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record, including recovering hundreds of millions for investors [4]. - Investors are advised to select qualified legal counsel with a proven history in similar cases, as not all firms have comparable experience or resources [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7].

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Red Cat Holdings, Inc. (NASDAQ: RCAT) between March 18, 2022 and January 15, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Red Cat securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Petco Health and Wellness Company, Inc. (“Petco” or the “Company”) (NASDAQ: WOOF) securities between January 14, 2021 and June 5, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants made false a ...